Armando Orlandi· @ArmandOrlandi · X·· 2 天前评分70
正文 · 原文
Cowabunga! 🌊 Riding the Early & Adjuvant Breast Cancer Wave 🏄🏻♂️🤙🏻 from #ESMO26
NATALEE, 6 yrs: ribociclib overall survival hazard ratio 0.81, +2.1%.
Encouraging, concordant, consistent. But: no alpha, nominal p, fragility ~2–3 deaths.
@OncoDaily #OncoDailyAmbassador
@OncoAlert
135 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Armando Orlandi · x.com